Top

Cancer Immunology, Immunotherapy

Published in:

01-09-1999 | REVIEW

Tumor-induced immune dysfunction

Authors: Rolf Kiessling, Ken Wasserman, Shigetoshi Horiguchi, Koji Kono, Jan Sjöberg, Pavel Pisa, Max Petersson

Published in: Cancer Immunology, Immunotherapy | Issue 7/1999

Title: Tumor-induced immune dysfunction
Authors: Rolf Kiessling
Ken Wasserman
Shigetoshi Horiguchi
Koji Kono
Jan Sjöberg
Pavel Pisa
Max Petersson
Publication date: 01-09-1999
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s002620050586

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 7/1999

Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies

In situ T cells in melanoma

How tumors escape immune destruction and what we can do about it

Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour

Function and dysfunction of CD4+ T cells in the immune response to melanoma

Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer